We use cookies for a better user experience. Read our Privacy Policy

I Agree

Post-operative Nausea and Vomiting (PONV) Market

Post-operative Nausea and Vomiting (PONV) Market (Treatment Type - Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacological Treatment; Distribution Channel - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Post-operative Nausea and Vomiting (PONV) Market - Snapshot

The global post-operative nausea and vomiting (PONV) market is growing at a significant rate due to bourgeoning incidence rate of post-operative complications and increasing demand for combination therapy, as well as introduction of promising drugs in this segment across the globe. The global PONV market was valued at US$ 1,608.6 Mn in 2017. It is projected to register a compound annual growth rate (CAGR) of 8.1% from 2018 to 2026 to reach a value of the US$ 3,174.1 Mn by 2026. The market is witnessing a relatively moderate growth owing to increase in patient population experiencing post-operative nausea and vomiting and rise in the rate of adoption of combination therapies as well as non-pharmacological treatment modes globally.

According to treatment guidelines, the suggested pharmacologic anti-emetics for prophylaxis  of PONV in adults include serotonin antagonists; such as, ramosetron, granisetron, palonosetron, ondansetron, dolasetron, and tropisetron, neurokinin-1 (NK-1) receptor antagonists; such as aprepitant, and rolapitant, steroids; such as dexamethasone and methylprednisolone, dopamine antagonists as transdermal scopolamine [TDS] and others; such as butyrophenones as well as antihistamines (dimenhydrinate and meclizine). Postoperative nausea and vomiting is considered a major clinical issue that can diminish a patient’s quality of life. Additionally, PONV leads to an increase in perioperative costs as well as morbidity, lengthens stay at the post-anesthesia care unit, increases hospital stay, delays the time taken by the patient to go back to work, and results in readmissions. Irrespective of the availability of multiple tools to segment patients as per PONV development risk criteria and treatment guidelines, physicians are unable to methodically address prophylaxis or treatment of PONV in a uniform manner through pharmacologic or non-pharmacologic strategies.

post-operative-nausea-vomiting-market.jpg

Major factors boosting the growth of the post-operative nausea and vomiting market include large number of surgeries performed and rise in the rate of postoperative complications, such as, dizziness, vomiting, and nausea. However, strict regulatory approvals and high health care expenditure are predicted to hamper the growth of the PONV market during the forecast period.

The global post-operative nausea and vomiting (PONV) market has been divided into three segments based on treatment type, distribution pattern, and geography. In terms of treatment type, the PONV market has been segmented into serotonin antagonists, steroids, dopamine antagonists, NK-1 receptor antagonists, others, and non-pharmacological treatment. Serotonin antagonist is expected to command the dominant share of the market owing to its proven safety profile and effectiveness, as well as for being physicians’ first preference drug in the management of post-operative nausea and vomiting. The non-pharmacologic treatment segment is expected to expand at a CAGR of 7.6% by 2026, owing to cost-effectiveness of the methods, such as, acupuncture, acupressure, and electrical acustimulation in the treatment of post-operative nausea and vomiting.

In terms of distribution pattern, the global post-operative nausea and vomiting (PONV) market has been classified into hospital pharmacies, online pharmacies, and retail pharmacies and online stores. The hospital pharmacies segment constitutes a major share of the PONV market owing to rising investment in the hospital sector, particularly in emerging countries, which is boosting the number of hospitals in these countries. This, in turn, is anticipated to increase the number of hospital pharmacies, thus improving accessibility to medications used in the treatment of PONV.

Geographically, the post-operative nausea and vomiting (PONV) market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the leading share of the global PONV market in 2017, followed by Europe, with a substantial market share. Presence of a large base of surgical patients as well as readiness among patients to pay extra money in order to avoid post-operative complications are expected to propel the PONV market in North America during the forecast period. Europe commands the second leading share of the global post-operative nausea and vomiting (PONV) market. High incidence rate of PONV among surgical patients in Europe and rise in R&D expenditure in pharmaceuticals are projected to lead to a large market size of the region.

Leading players operating in the global post-operative nausea and vomiting (PONV) market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., and GlaxoSmithKline Corporation.

The global PONV market has been segmented as follows:

Treatment

  • Serotonin Antagonists
  • Steroids
  • Dopamine Antagonists
  • NK-1 Receptor Antagonists
  • Others
  • Non-pharmacologic Treatment

Application

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies and Drug Stores

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the total market worth of post-operative nausea and vomiting (PONV) market?

The global post-operative nausea and vomiting (PONV) market was worth US$ 1,608.6 Mn and is projected to reach a value of US$ 3,174.1 Mn by the end of 2026

What is the anticipated CAGR of the post-operative nausea and vomiting (PONV) market in the forecast period?

Post-operative nausea and vomiting (PONV) market is anticipated to grow at a CAGR of 8.1% during the forecast period

Which region is expected to project the highest market share in the global post-operative nausea and vomiting (PONV) market?

North America accounted for a major share of the global post-operative nausea and vomiting (PONV) market

What are the key driving factors for the growth of the post-operative nausea and vomiting (PONV) market?

The growth of the post-operative nausea and vomiting market include large number of surgeries performed and rise in the rate of postoperative complications, such as, dizziness, vomiting, and nausea

Who are the key players in the global post-operative nausea and vomiting (PONV) market?

Key players in the global post-operative nausea and vomiting (PONV) market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., and GlaxoSmithKline Corporation

    Chapter 1 Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

    Chapter 2 Assumptions and Research Methodology

    Chapter 3 Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

    Chapter 4 Market Overview
    4.1. Introduction
    4.2. Key Industry Developments

    Chapter 5 Market Dynamics
    5.1. Drivers
    5.2. Restraints
    5.3. Opportunities
    5.4. Trends
    5.5. Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
    5.6. Global Post-operative Nausea and Vomiting (PONV) Market Outlook

    Chapter 6 Market Outlook
    6.1. Absolute Surgical Procedure Volume, by Region
    6.2. Incidence of Post-operative Nausea and Vomiting, by Region, (2017 - Estimated)
    6.3. Post-operative Nausea and Vomiting (PONV) Market: Pipeline Analysis

    Chapter 7 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
    7.1. Key Findings
    7.2. Introduction
    7.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
           7.3.1. Serotonin Antagonists
           7.3.2. Steroids
           7.3.3. Dopamine Antagonists
           7.3.4. NK-1 receptor Antagonists
           7.3.5. Non-Pharmacologic Treatment
    7.4. Market Attractiveness Analysis, by Treatment Type

    Chapter 8 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
    8.1. Key Findings
    8.2. Global PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
           8.2.1. Hospital Pharmacies
           8.2.2. Online Pharmacies
           8.2.3. Retail Pharmacies and Drug Stores
    8.3. Global PONV Market Attractiveness Analysis, by Distribution Channel
    8.4. Key Trends

    Chapter 9 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Global Market Scenario
    9.3. Global PONV Market Value (US$ Mn) Forecast, by Region, 2018–2026
           9.3.1. North America
           9.3.2. Europe
           9.3.3. Asia Pacific
           9.3.4. Latin America
           9.3.5. Middle East & Africa
    9.4. Global PONV Market Attractiveness Analysis, by Region

    Chapter 10 North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
    10.1. Key Findings
    10.2. North America PONV Market Size (US$ Mn) Forecast, by Country, 2018–2026
           10.2.1. U.S.
           10.2.2. Canada
    10.3. North America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
           10.3.1. Serotonin Antagonists
           10.3.2. Steroids
           10.3.3. Dopamine Antagonists
           10.3.4. NK-1 receptor Antagonists
           10.3.5. Non-pharmacologic Treatment
    10.4. North America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
           10.4.1. Hospital Pharmacies
           10.4.2. Online Pharmacies
           10.4.3. Retail Pharmacies and Drug Stores
    10.5. North America PONV Market Attractiveness Analysis
           10.5.1. By Country
           10.5.2. By Treatment Type
           10.5.3. By Distribution Channel

    Chapter 11 Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
    11.1. Key Findings
    11.2. Europe PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           11.2.1. Germany
           11.2.2. U.K.
           11.2.3. France
           11.2.4. Italy
           11.2.5. Spain
           11.2.6. Russia
           11.2.7. Rest of Europe
    11.3. Europe PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
           11.3.1. Serotonin Antagonists
           11.3.2. Steroids
           11.3.3. Dopamine Antagonists
           11.3.4. NK-1 receptor Antagonists
           11.3.5. Non-Pharmacologic Treatment
    11.4. Europe PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
           11.4.1. Hospital Pharmacies
           11.4.2. Online Pharmacies
           11.4.3. Retail Pharmacies and Drug Stores
    11.5. Europe PONV Market Attractiveness Analysis
           11.5.1. By Country
           11.5.2. By Treatment Type
           11.5.3. By Distribution Channel

    Chapter 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
    12.1. Key Findings / Developments
    12.2. Market Overview
    12.3. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           12.3.1. China
           12.3.2. India
           12.3.3. Japan
           12.3.4. Australia & New Zealand
           12.3.5. Rest of Asia Pacific
    12.4. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
           12.4.1. Serotonin Antagonists
           12.4.2. Steroids
           12.4.3. Dopamine Antagonists
           12.4.4. NK-1 receptor Antagonists
           12.4.5. Non-Pharmacologic Treatment
    12.5. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
           12.5.1. Hospital Pharmacies
           12.5.2. Online Pharmacies
           12.5.3. Retail Pharmacies and Drug Stores
    12.6. Asia Pacific PONV Market Attractiveness Analysis
           12.6.1. By Country
           12.6.2. By Treatment Type
           12.6.3. By Distribution Channel

    Chapter 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
    13.1. Key Findings / Developments
    13.2. Market Overview
    13.3. Latin America PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           13.3.1. Brazil
           13.3.2. Mexico
           13.3.3. Rest of Latin America
    13.4. Latin America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
           13.4.1. Serotonin Antagonists
           13.4.2. Steroids
           13.4.3. Dopamine Antagonists
           13.4.4. NK-1 receptor Antagonists
           13.4.5. Non-Pharmacologic Treatment
    13.5. Latin America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
           13.5.1. Hospital Pharmacies
           13.5.2. Online Pharmacies
           13.5.3. Retail Pharmacies and Drug Stores
    13.6. Latin America PONV Market Attractiveness Analysis
           13.6.1. By Country
           13.6.2. By Treatment Type
           13.6.3. By Distribution Channel

    Chapter 14 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
    14.1. Key Findings / Developments
    14.2. Market Overview
    14.3. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           14.3.1. GCC Countries
           14.3.2. South Africa
           14.3.3. Israel
           14.3.4. Rest of Middle East & Africa
    14.4. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
           14.4.1. Serotonin Antagonists
           14.4.2. Steroids
           14.4.3. Dopamine Antagonists
           14.4.4. NK-1 receptor Antagonists
           14.4.5. Non-Pharmacologic Treatment
    14.5. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
           14.5.1. Hospital Pharmacies
           14.5.2. Online Pharmacies
           14.5.3. Retail Pharmacies and Drug Stores
    14.6. Middle East & Africa PONV Market Attractiveness Analysis
           14.6.1. By Country
           14.6.2. By Treatment Type
           14.6.3. By Distribution Channel

    Chapter 15 Competition Landscape
    15.1. Global Market Player - Competition Matrix (By Tier and Size of companies)
    15.2. Key Players and Their Competitive Positioning
    15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
           15.3.1. Acacia Pharma
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Product Portfolio
                     15.3.1.3. SWOT Analysis
                     15.3.1.4. Strategic Overview
           15.3.2. F. Hoffmann La Roche Ltd.
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Product Portfolio
                     15.3.2.3. SWOT Analysis
                     15.3.2.4. Strategic Overview
           15.3.3. ANI Pharmaceuticals
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Product Portfolio
                     15.3.3.3. SWOT Analysis
                     15.3.3.4. Financial Overview
                     15.3.3.5. Strategic Overview
           15.3.4. Sanofi
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Product Portfolio
                     15.3.4.3. SWOT Analysis
                     15.3.4.4. Financial Overview
                     15.3.4.5. Strategic Overview
           15.3.5. GlaxoSmithKline Corporation
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Product Portfolio
                     15.3.5.3. SWOT Analysis
                     15.3.5.4. Financial Overview
                     15.3.5.5. Strategic Overview
           15.3.6. Eisai Co., Inc.
                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Product Portfolio
                     15.3.6.3. SWOT Analysis
                     15.3.6.4. Financial Overview
                     15.3.6.5. Strategic Overview
           15.3.7. Merck KGaA
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Product Portfolio
                     15.3.7.3. SWOT Analysis
                     15.3.7.4. Financial Overview
                     15.3.7.5. Strategic Overview
           15.3.8. Novartis AG
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Product Portfolio
                     15.3.8.3. SWOT Analysis
                     15.3.8.4. Financial Overview
                     15.3.8.5. Strategic Overview
           15.3.9. Helsinn Holding Co.
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Product Portfolio
                     15.3.9.3. SWOT Analysis
                     15.3.9.4. Financial Overview
                     15.3.9.5. Strategic Overview
           15.3.10. Camurus AB
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Product Portfolio
                     15.3.10.3. SWOT Analysis
                     15.3.10.4. Financial Overview
                     15.3.10.5. Strategic Overview

    List of Tables:

    Table 01 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 02 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 03 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Region, 2016–2026
    Table 04 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country, 2016–2026
    Table 05 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 06 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 07 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 08 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 09 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 10 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 11 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 14 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 15 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 16 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 17 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 18 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

    List of Figures:

    Figure 01 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn), by Distribution Channel, 2017
    Figure 02 Global Post-operative Nausea and Vomiting (PONV) Market Size, by Treatment Type (US$ Mn), 2017
    Figure 03 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn), by Region, 2017 and 2026
    Figure 04 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
    Figure 05 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
    Figure 06 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2017 and 2026
    Figure 07 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Serotonin Antagonists, 2016–2026
    Figure 08 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Steroids, 2016–2026
    Figure 09 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Dopamine Antagonists, 2016–2026
    Figure 10 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by NK1 Receptor Antagonists, 2016–2026
    Figure 11 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
    Figure 12 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Non-pharmacologic Treatment, 2016–2026
    Figure 13 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type
    Figure 14 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
    Figure 15 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 16 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2016–2026
    Figure 17 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2016–2026
    Figure 18 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies and Drug Stores, 2016–2026
    Figure 19 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2016 and 2025
    Figure 20 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region
    Figure 21 North America Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country, 2017 and 2026
    Figure 22 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country, 2018–2026
    Figure 23 North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
    Figure 24 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
    Figure 25 North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
    Figure 26 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 27 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 28 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 29 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 30 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
    Figure 31 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
    Figure 32 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
    Figure 33 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 34 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 35 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 36 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 37 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
    Figure 38 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
    Figure 39 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
    Figure 40 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 41 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 42 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 43 Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 44 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
    Figure 45 Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
    Figure 46 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
    Figure 47 Latin America Postoperative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 48 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 49 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 50 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 51 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
    Figure 52 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
    Figure 53 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
    Figure 54 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 55 Acacia Pharma Research & Development Cost, 2015 – 2017 (US$ Mn)
    Figure 56 F. Hoffmann-La Roche Ltd Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 57 F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
    Figure 58 F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
    Figure 59 F. Hoffmann-La Roche Ltd Research & Development Cost, 2015 - 2017 (US$ Mn)
    Figure 60 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 61 Novartis AG Breakdown of Net Sales, by Region, 2017
    Figure 62 Novartis AG Breakdown of Net Sales, by Business Segment, 2017
    Figure 63 Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2017
    Figure 64 ANI Pharmaceuticals Inc. Research & Development Cost, 2015 - 2017 (US$ Mn)
    Figure 65 ANI Pharmaceuticals Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 66 Camurus AB Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 67 Camurus AB Breakdown of Net Sales, by Region, 2017
    Figure 68 Camurus AB Breakdown of Net Sales, by Business Segment, 2017
    Figure 69 Camurus AB Research & Development Cost (US$ Mn), 2016–2017
    Figure 70 Sanofi Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 71 Sanofi Breakdown of Net Sales, by Region, 2017
    Figure 72 Sanofi Breakdown of Net Sales, by Business Segment, 2017
    Figure 73 Sanofi Breakdown of Net Sales, by Pharmaceuticals, 2017 
    Figure 74 Eisai Inc. Breakdown of Net Sales, by Region, 2017
    Figure 75 Eisai Inc. R&D Intensity Company Level (US$ Mn), 2016–2017
    Figure 76 Eisai Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
    Figure 77 Helsinn Healthcare S.A. Breakdown of Net Sales, by Region, 2016 (%)
    Figure 78 Helsinn Healthcare S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2016
    Figure 79 Merck Group, Revenue (US$ Mn), 2015-2017
    Figure 80 EMEND Revenue (US$ Mn), 2015-2017
    Figure 81 EMEND Revenue, by Region (%), 2017
    Figure 82 GSK’s Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
    Figure 83 R&D Expenditure (US$ Mn), GSK Group, 2015-2017
    Figure 84 Breakdown of GSK’s Vaccines Segment Net Sales, by Region, 2017
    Figure 85 Breakdown of GSK’s Net Sales, by Business Segment, 2017

Copyright © Transparency Market Research, Inc. All Rights reserved